Background Long-term evaluations 10 years after Roux-en-Y gastric bypass (RYGB) are limited. We report the development in weight and cardiovascular risk factors during 10 years after laparoscopic RYGB, with evaluation of gastrointestinal symptoms and quality of life (QoL) at 10-year follow-up. Methods We performed a prospective longitudinal cohort study. Patients operated with laparoscopic RYGB from May 2004 to November 2006 were invited to 10-year follow-up consultations. Gastrointestinal Symptom Rating Scale (GSRS) questionnaire and two QoL questionnaires were used for analyses of gastrointestinal symptoms and QoL. Results A total of 203 patients were operated; nine (4.4%) died during follow-up. Of 194 eligible patients, 124 (63.9%) attended 10-year follow-up consultations. Percent excess weight loss (%EWL) and percent total weight loss (%TWL) at 10 years were 53.0% and 24.1%, respectively. %EWL > 50% was seen in 53.2%. Significant weight regain (≥15%) from 2 to 10 years was seen in 63.3%. Remission rates of type 2 diabetes, dyslipidemia, and hypertension were 56.8%, 46.0%, and 41.4%, respectively. Abdominal operations beyond 30 days after RYGB were reported in 33.9%. Internal hernia and ileus (13.7%) and gallstone-related disease (9.7%) were the most common causes. Vitamin D deficiency (<50nmol/L) was seen in 33.3%. At 10 years, bothersome abdominal pain and indigestion symptoms (GSRS scores ≥3) were reported in 42.9% and 54.0%, respectively, and were associated with low QoL. Conclusion We observed significant weight loss and remission of comorbidities 10 years after RYGB. Significant weight regain occurred in a substantial subset of patients. Gastrointestinal symptoms were common and negatively impacted QoL.
Surgery
Patients were advised a three-week low-calorie diet (1000 kcal/day) prior to surgery. RYGB was performed laparoscopically in all patients, with a gastric pouch of about 25 ml, an antecolic alimentary limb of 150 cm, and a biliopancreatic limb of 50 cm [21] . The gastrojejunostomy was made using a 45 mm linear stapler and the defect after the stapler was closed with running sutures from each corner. Mesenteric defects were not routinely closed during the study period. Patients were operated by the same two surgeons.
Follow-up
Patients were offered follow-up consultations at 6-8 weeks, 6 months, 1, 2, 3, and 5 years after surgery. To reduce the risk of gallstone formation in patients with the gall bladder in situ, we recommend oral ursodeoxycholic acid (Ursofalk, Dr.Falk Pharma GmbH, Germany) 250 mg twice a day for six months after RYGB. Oral multivitamins (one tablet), iron (100-200 mg), vitamin D (800 IU), and calcium (1000 mg) supplementation daily, and intramuscular vitamin B12 injections (1 mg every third month) were routinely prescribed when discharged after surgery. Serum levels were evaluated at follow-up and recommendations for any adjustments were given as needed. Ten-year follow-up consultations were performed between June 2015 and June 2018.
Definitions of weight loss
Percent excess weight loss (%EWL) was defined as: ((initial weight − follow-up weight)/(initial weight − ideal weight) * 100. Ideal weight corresponds to a BMI of 25 kg/ m 2 . Percent total weight loss (%TWL) was defined as: ((initial weight − follow-up weight)/initial weight)) * 100. Percent weight regain (%WR) was calculated as: (current weight − weight at two years)/(preoperative weight − weight at two years) * 100, and was regarded significant if ≥ 15% [22, 23] .
Cardiovascular risk factors
Type 2 diabetes was defined as fasting plasma glucose ≥ 7 mmol/L, glycated hemoglobin (HbA1c) ≥ 6.5% or the use of diabetic medication. Hypertension was defined by systolic blood pressure ≥ 140/90 mmHg or the use of antihypertensive medication. Dyslipidemia was defined by fasting LDL cholesterol ≥ 3.0 mmol/l, HDL cholesterol < 1.0 mmol/L (men) or < 1.3 mmol/L (women), triglycerides > 1.7 mmol/l, total cholesterol/HDL cholesterol ratio > 5 or the use of lipid-lowering medication. Metabolic syndrome was defined according to the International Diabetes Federation, and included waist circumference, type 2 diabetes, hypertension, and dyslipidemia.
Nutritional deficiencies
According to WHO's classification, anemia was defined as hemoglobin < 12 g/dL in women and < 13 g/dL in men. Iron deficiency was defined as ferritin < 15 µg/L. Vitamin B12 and vitamin B9 deficiencies were defined as < 150 ρmol/L and < 10 nmol/L, respectively.
Levels of 25-OH-vitamin D < 50 nmol/L defined vitamin D deficiency.
Abdominal surgery after RYGB
All abdominal reoperations during the 10 years after RYGB were registered. Reoperations were defined as early (within 30 days after surgery) and late (beyond 30 days after surgery).
Gastrointestinal symptoms
The Gastrointestinal Symptom Rating Scale (GSRS, 1-week recall) was distributed at the 10-year follow-up consultations. GSRS yields total score and five syndrome scores (abdominal pain-, gastrointestinal reflux-, diarrhea-, indigestion-, and constipation syndrome) on a scale from 1 to 7 (1 = no discomfort, 7 = severe discomfort) [24] . We used the mean value of ≥ 3 for each syndrome as cutoff value for defining bothersome symptoms.
Quality of life
SF-36v2 (4-week recall) was used to evaluate QoL. It provides eight health domain scores and two summary scores (physical and mental) from 0 to 100 (0 = maximum disability, 100 = no disability). SF-36v2 was scored using Health Outcomes Scoring Software version 5.1 (Optum Inc.) [25] .
Obesity-related Problems scale (OP scale) was used to measure the impact of obesity on psychosocial aspects of life and also QoL. Transformed scale scores ranged from 0 (no impairment) to 100 (maximum impairment), and scores < 40 indicated mild impairment in psychosocial functioning, scores 40-59 indicated moderate impairment and scores ≥ 60 indicate severe impairment [26] .
Statistical analyses
Continuous data were compared using Student's t test.
McNemar's test or Chi-Square/χ 2 test was used for comparison of categorical variables. Continuous variables are presented as means with standard deviations (SD) or median with 25th and 75th quartile, and categorical variables as number (portion in percent, %). Statistical analyses were performed using IBM SPSS® Statistics version 25 (IBM Corp, Armonk, New York, USA).
Results

Participants
There was no 30-day mortality after RYGB. Nine of 203 (4.4%) patients operated died during follow-up. Among 194 patients eligible for 10-year consultations, 124 (63.9%) patients attended 10-year follow-up. Of these, 121 (97.6%) patients had also met to 5-year consultations. Median duration of follow-up was 10.8 (10.7-11.0) years. Mean age at 10 year was 50.9 (9.1) years, and 95/124 (76.6%) were females.
Weight development
Weight development is given in Table 1 . At 5-and 10-year, weight loss was 37.0 (21.8) kg and 32.9 (17.3) kg, and change in BMI was 12.4 (5.7) kg/m 2 and 10.7 (6.1) kg/m 2 , respectively. In the entire cohort, %TWL > 20% was seen in 86/120 (71.7%) at 5 and in 78/124 (62.9%) at 10-year follow-up. Development in BMI during 10 years after RYGB is illustrated in Fig. 1 .
In 83 (66.9%) patients with preoperative BMI < 50 kg/ m 2 , weight loss and BMI change 5 and 10 years after RYGB was 33.6 (14.1) kg and 30.2 (16.6) kg, and 11.2 (4.8) kg/m 2 and 9.6 (5.5) kg/m 2 , respectively. The corresponding numbers in 41 (33.1%) patients with preoperative BMI ≥ 50 kg/m 2 was significantly higher: 44.2 (18.2) kg and 38.4 (17.7) kg, and 14.9 (6.4) kg/m 2 and 12.8 (6.7) kg/m 2 , respectively. Patients with preoperative Table 1 Weight development from baseline to 10 years after laparoscopic Roux-en-Y gastric bypass (RYGB)
The changes during follow-up (from baseline to 5 and 10 years after RYGB, as well as from 5 to 10 years after RYGB) for the entire population and for both BMI groups, were significant for all variables (P < 0.05, paired sample t test and McNemar's test as appropriate) except for insignificant changes in %WR ≥ 15% between 5 and 10 years after RYGB Categorical variables are given as portion (%), continuous variables as mean (standard deviation) or median (25th and 75th quartile) as appropriate BMI Body mass index, %EWL percent excess weight loss, %TWL percent total weight loss, %WR percent weight regain BMI < 50 kg/m 2 had significantly higher weight and BMI loss (P < 0.005). The differences in all other parameters between the two BMI groups in Table 1 were insignificant.
Cardiovascular risk factors
For the entire cohort, the prevalence of type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome decreased significantly from baseline to both 5 years and 10 years after RYGB (Fig. 2 ). This was also true when categorized according to preoperative BMI groups of BMI < 50 kg/m 2 and BMI ≥ 50 kg/m 2 . From 5 to 10 years after RYGB, we found a significant increase in the prevalence of metabolic syndrome for the entire population as well as for patients with preoperative BMI < 50 kg/m 2 . Lipid profiles are illustrated in Fig. 3 . Median HbA1c levels were 5.8 (5.4-6.2) at baseline, and decreased significantly to 5.6 (5.4-5.9) at 5 (P < 0.001) and to 5.5 (5.2-5.8) at 10-year follow-up (P < 0.001). The decrease from 5 to 10 year follow-up was significant (P < 0.001).
Remission rates for comorbidities for the entire population are given in Fig. 2. 10-year remission rates for type 2 diabetes, dyslipidemia, hypertension, and metabolic syndrome for patients with preoperative BMI < 50 kg/ m 2 were: 50.0%, 44.8%, 39.1%, and 43.8%, respectively. Corresponding rates for patients with preoperative BMI ≥ 50 kg/m 2 were: 72.7%, 48.5%, 46.7%, and 73.3%, respectively.
Nutritional deficiencies and use of supplements
In the entire cohort, anemia was seen in 6/107 (5.6%) patients at baseline, in 19/100 (19.0%) at 5-year followup (P = 0.007) and in 25/124 (20.2%) at 10-year followup (P = 0.004). Iron deficiency was seen in 5/99 (5.1%) at baseline, in 31/102 (30.4%) at 5-year follow-up (P < 0.001), and in 22/124 (17.7%) at 10-year follow-up (P = 0.004). The reduction in iron deficiency from 5 to 10-year follow-up was significant (P = 0.009). During follow-up, 17/124 (13.7%) received intravenous iron infusion treatment. The prevalence of vitamin D deficiency was stable from 26/83 (31.3%) at 5 to 41/123 (33.3%) at 10 years (P = 0.711).
At least one vitamin supplement were used by 114/124 (91.9%) patients at 10-year follow-up. The main supplements used were vitamin B12 (85.1%), vitamin D (64.9%) and multivitamins (64.9%), calcium (49.1%), and iron (44.7%).
Abdominal operations after RYGB
A total of 12/124 (9.7%) of patients had abdominal reoperation due to early complications. Late abdominal surgery was reported in 42/124 (33.9%) patients ( Table 2 ). Mean OP-score was 37.5 (4.2-55.2). Mild, moderate, and severe impairment of social activities were seen in 50/86 (58.1%), 15/86 (17.4%), and 20/86 (23.3%), respectively. There were no significant differences in SF-36v2 scores and OP-scores in patients with preoperative BMI < 50 kg/ m 2 and ≥ 50 kg/m 2 .
Abdominal and gastrointestinal symptoms
Quality of life
Discussion
Our study enlightens long-term outcomes after laparoscopic RYGB. Weight loss was significant and sustained, as were beneficial effects concerning cardiovascular risk factors. However, these health benefits were accompanied by health risks such as repeated abdominal surgery, weight regain, and long-term gastrointestinal symptoms that may negatively influence QoL.
The %EWL and %TWL in our population 10 years after RYGB were comparable to what reported by others [7, [10] [11] [12] [13] [14] [15] 17] . In our study, %EWL significantly decreased while %WR significantly increased from 5 to 10 years after RYGB. More focus on weight regain after RYGB is needed. Besides educating patients on appetite regulation, dietary choices, and physical activity, increased focus on mechanisms of weight regain may influence weight stability during follow-up [27] . At 10-year follow-up, patients with preoperative BMI ≥ 50 kg/m 2 had significantly higher weight (kg) and BMI loss compared to patients with preoperative BMI < 50 kg/m 2 . We also found that patients with preoperative BMI < 50 kg/m 2 had more weight regain 10 years after RYGB. Therefore, the differences in %EWL and %TWL in the two BMI groups were insignificant at 10 year, this in contrast to a previous study that found significant more %EWL in patients with preoperative BMI < 50 kg/m 2 10-13 years after RYGB [13] .
The prevalence of type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome decreased significantly during follow-up (Fig. 2) . The remission rate of 56.8% for type 2 diabetes in the entire population compares to other reports [11, 13] . Between 5-and 10-year follow-up, we found significant increase in metabolic syndrome for the entire population as well as for patients with preoperative BMI < 50 kg/ m 2 . This increase reflects weight regain and increased weight circumference during follow-up in these patients. Beneficial lipid profiles, however, especially with significant increase in HDL, continued in the long-term as seen in Fig. 3 . Patients with preoperative BMI ≥ 50 kg/m 2 had higher remission rates for all comorbidities than patients with preoperative BMI < 50 kg/m 2 , both at 5-and 10-year follow-up, and their remission rates continued to improve to 10 years (data not shown). The metabolic benefits of RYGB may thus continue for a longer period after surgery in this subgroup of patients. A previous study evaluating 5-year outcome after RYGB has reported remission rates to be similar between the two BMI groups [28] . To our knowledge, none of the previous 10-year reports has categorized the prevalence and remission rates of comorbidities after RYGB according to the preoperative BMI. Further studies are therefore encouraged to explore our findings.
Multivitamins were used by 64.9% of our patients 10 years after surgery, which is much higher compared to another report [9] . Although vitamin D supplements were used by 64.9%, vitamin D deficiency was observed in 33.3% at 10 years. This is of concern in regard to bone health. Vitamin D deficiency in our population was lower than 58.3% reported by another study [12] .
The data on surgical complications and reoperations reflect our initial experience with RYGB. Proficiency in gastric bypass surgery may include 100 patients or more [21] . During follow-up, at least 33.9% of our patients underwent abdominal surgery. Rates of abdominal surgery after RYGB otherwise vary between 14.6 and 45% [12] [13] [14] . The most common indications for surgery were internal hernia and ileus. Although not performed during the study period, closure of mesenterial defects is routine practice at our institution. Our 9.7% rate of cholecystectomy is lower than what is reported by others, which could be related to our recommended use of prophylactic ursodeoxycholic acid [6, 12] .
According to the GSRS scores, 42.9% of the patients had bothersome abdominal pain symptoms 10 years after RYGB, with no significant difference between the two preoperative BMI groups. Although GSRS is a 4-week recall questionnaire, the number is still worrying. We do not have preoperative data, and the preoperative symptom burden may have been high. We have recently published before and after RYGB data reporting similar GSRS scores in 28.1% patients two years after surgery [19] . In another study, we found that 32.8% of the patients reported bothersome abdominal pain symptoms 5 years after RYGB [20] . Patients may consider abdominal pain as a part of the postoperative status and may underreport it. We found that 54.6% of the patients had symptoms related to indigestion. Increased focus on dietary choices and habits may aid in reducing these symptoms. Increased attention should be given to the risk of postoperative abdominal pain and symptoms, and information of this risk should be given to the patients in the preoperative settings.
Mean SF-36v2 and OP scale scores were comparable with one previous study; however, our observed rate of 23.3% patients with severe impairment of psychosocial functioning (OP scale) was lower than the 63.5% previously reported [29] . Importantly, as we have previously shown, bothersome abdominal pain and gastrointestinal symptoms may negatively influence QoL after RYGB. Together with postoperative abdominal pain and symptoms, focus on aspects of quality of life and of psychosocial functioning should be part of the follow-up consultations as well.
There are limitations to our study. Data on abdominal surgery after RYGB performed at other institutions were mostly patient reported, and such procedures may have been underreported. We did not have available preoperative data concerning QoL and gastrointestinal symptoms. The single-center design may reduce the external validity of our findings. Strengths of the study include the cohort design and the comprehensive and detailed follow-up from baseline to 10 years after RYGB, with paired data from several time points. Importantly, all patients were followed by in-office consultations at the same bariatric clinic. Comparable single-center and in-office long-term follow-up rates (> 10 years), has only been seen in few long-term studies [8, 11, 17, 18] . High attrition rates are a challenge in longterm evaluations post bariatric surgery. To improve followup we used dedicated physicians and repeated reminders with flexibility in regard to scheduling appointments. The patient-reported outcome measures add patient perspectives to our objective findings, and are highly relevant for health care quality evaluations.
Conclusion
Significant and sustained weight loss and reduction in cardiovascular risk factors were observed 10 years after RYGB. Gastrointestinal symptoms were common and may influence QoL. The findings support the use of RYGB in selected patients. the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
